CAS: 192575-19-2 - pyridoxal-phosphate-6-azophenyl-2',4'- disulfoni
Formula:C14H10N3Na4O12PS2
- Synonyms:
- PPADS, Tetrasodium Salt
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | PPADS Tetrasodium REF: IN-DA01CC9JCAS: 192575-19-2 | 95.0% | To inquire | Mon 16 Dec 24 |
 | PPADS tetrasodium REF: TM-T16564CAS: 192575-19-2 | 95% - ≥95% | To inquire | Tue 18 Feb 25 |
 | PPADS Tetrasodium REF: TR-P698980CAS: 192575-19-2 | - - - | - - - | Discontinued product |
 | PPADS tetrasodium REF: 3D-SHA57519CAS: 192575-19-2 | Min. 95% | - - - | Discontinued product |
PPADS Tetrasodium
CAS:192575-19-2
Formula:
C14H10N3Na4O12PS2
Purity:
95.0%
Color and Shape:
Solid
Molecular weight:
599.3049
Ref: IN-DA01CC9J
| 1mg | 193.00 € | ||
| 5mg | 619.00 € | ||
| 10mg | To inquire |
Estimated delivery in United States, on Monday 16 Dec 2024
PPADS tetrasodium
CAS:192575-19-2
PPADS tetrasodiuma is a P2X receptor antagonist and an inhibitor of the inverse mode of …
Formula:
C14H10N3Na4O12PS2
Purity:
95% - ≥95%
Color and Shape:
Solid
Molecular weight:
599.3
Ref: TM-T16564
| 1mg | 51.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
PPADS Tetrasodium
CAS:192575-19-2
Stability Unstable in Aqueous Solution Applications PPADS Tetrasodium is an non-selective purinergic antagonists of P2 …
Formula:
C14H10N3Na4O12PS2
Color and Shape:
Dark Orange to Dark Red Solid
Molecular weight:
599.30
Ref: TR-P698980
| 25mg | Discontinued | Request information | |
| 250mg | Discontinued | Request information |
PPADS tetrasodium
CAS:192575-19-2
PPADS is a pyridoxal phosphate-dependent adenosine diphosphate (ADP) ribose hydrolase inhibitor that blocks the formation …
Formula:
C14H10N3Na4O12PS2
Purity:
Min. 95%
Molecular weight:
599.3 g/mol
Ref: 3D-SHA57519
| 5mg | Discontinued | Request information | |
| 10mg | Discontinued | Request information | |
| 25mg | Discontinued | Request information | |
| 50mg | Discontinued | Request information | |
| 100mg | Discontinued | Request information | |
| 250mg | Discontinued | Request information |
